BSc (Hons), MBBS (Hons) MEd MRCP
Novo Nordisk Clinical Research Training Fellow & DPhil Student
I am a Specialist Registrar and Clinical Research Fellow in Diabetes, Endocrinology and Metabolism. My undergraduate training was undertaken at Imperial College London from where I hold a BSc in Pharmacology and Toxicology and graduated in Clinical Medicine with Distinction. My postgraduate training includes the award of NIHR Academic Clinical Fellowships at Imperial College London and at Bart's and the London School of Medicine to pursue research in diabetes, obesity and metabolism, alongside my clinical practice. I also have considerable experience in medical education and clinical leadership. I hold a Masters in Education (MEd) and between 2010-11 I worked on secondment at the Department of Health as a Clinical Advisor to the National Medical Director for the NHS in England where my portfolio included work on quality improvement and clinical leadership programmes within the NHS.
My research is focused on non-alcoholic fatty liver disease (NAFLD), which is rapidly becoming the commonest cause of chronic liver disease worldwide and affects up to 70% of patients with Type 2 Diabetes Mellitus (T2DM). Based at the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) and the University of Oxford Centre for Clinical Magnetic Resonance (OCMR), I am investigating new treatments for NAFLD, including the utility of GLP-1 analogues as novel therapy, as well as investigating novel non-invasive techniques with which to stage and grade NAFLD and with which to assess treatment response.
l-phenylalanine modulates gut hormone release and glucose tolerance, and suppresses food intake through the calcium-sensing receptor in rodents.
Alamshah A. et al, (2017), Int J Obes (Lond), 41, 1693 - 1701
High risk populations: Attitudes to NAFLD among Diabetologists
Marjot T. et al, (2016), HEPATOLOGY, 64, 557A - 557A
L-arginine promotes gut hormone release and reduces food intake in rodents.
Alamshah A. et al, (2016), Diabetes Obes Metab, 18, 508 - 518
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?
Chin JL. et al, (2016), Front Pharmacol, 7
Complications of diabetes: progress, but significant challenges ahead.
Chowdhury TA. et al, (2014), Ann Transl Med, 2